76 results about "Paratuberculosis" patented technology

The use of free, extractable lipids found in bacteria for identification of bacterial species and subspecies is described. Bacteria have been found to differ sufficiently in their extracted lipid compositions to effect identification using thin layer chromatographic techniques. Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia mallei have been distinguished in this manner. Lipopeptides specific to Mycobacterium avium subspecies paratuberculosis, but not to the closely related bacterium Mycobacterium avium subspecies avium have also been used as a basis for bacterial subspecies identification using mass spectrometry and seroreactivity. Mass spectrometric analysis of total bacterial lipids of Burkholderia pseudomallei, Burkholderia thailandensis, and Burkholderia mallei, and mass spectrometric analysis of total bacterial lipids for Mycobacterium avium subspecies paratuberculosis and Mycobacterium avium subspecies avium, without further lipid separation, has shown that species and subspecies of bacteria may be identified using such analysis.

The fusion protein rESAT-6:CFP-10 is useful for differentiating infection of an animal with Mycobacterium bovis from exposure of the animal to other species of Mycobacteria, especially M. avium and M. avium subspecies paratuberculosis (Map). Cells stimulated with the fusion protein are capable of eliciting a variety of in vivo and in vitro responses (e.g. hypersensitivity skin response, IFN-γ, nitric oxide, and TNF-α) indicative of M. bovis infection. This invention will facilitate diagnosis of tuberculosis in cattle, reindeer and other susceptible animal species, thereby preventing unnecessary slaughter of uninfected animals suspected of having of the disease.

The invention relates to an establishing method of a serum diagnosing model of active tuberculosis, which has the following steps: step 1 is a serum source taking and preparing step which comprises an experiment group and a control group, the venous blood of a checked person is collected, serum and the rest are separately stored after serum separation at the temperature of -80 DEG C in a refrigerator for spare use; step 2 is the step of the mass spectrometric analysis of the serum and comprises sample treatment, protein plate check, spectrometric analysis and data acquisition; step 3 is the step of statistic analysis and the difference protein screening; step 4 is the step of establishing the diagnosing model, and Biomarker Pattern 5.0 software is used for establishing the model of diagnosing active tuberculosis. When the model is used for identifying the active tuberculosis and the control group, the sensitivity is 96.9 percent, the specificity is 97.8 percent, the positive predicating value and the negative predicating value are 97.7 percent and 97.1 percent, and the total accurate rate is 97.3 percent.

The present invention relates to materials and methods for identifying animals that are resistant or susceptible to diseases associated with intracellular parasites such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. More particularly, the present invention relates to the identification of a gene, called NRAMP1, which is associated with the susceptibility or resistance of an animal, such as an artiodactyla to diseases such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. Still more particularly, the present invention relates to the identification of specific sequences of bovine NRAMP1 which associate with resistance or susceptibility to ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis, and to the method of identifying said sequences to identify animals who are susceptible or resistant to disease.

The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Furthermore a single or multi-phase vaccine comprising the one or more immunogenic polypeptides is provided for administration for the prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Additionally, nucleic acid vaccines, capable of in vivo expression of the multi-phase vaccine comprising the one or more immunogenic polypeptides, is provided for prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis.

The invention discloses a specific marker (Rv3119 recombinant protein) of mycobacterium tuberculosis and discloses an application of the Rv3119 recombinant protein in preparation a tuberculosis diagnostic reagent and a tuberculosis diagnostic kit. The Rv3119 specific antigen provided by the invention has high sensitivity in detecting phthisis, is a B cell target antigen with relatively strong activity, can be applied in preparation of rapid detection kit for the tuberculosis, and is safe and reliable.

Described herein is a mycobacterium mutant, comprising at least one mutation in at least one gene sequence encoding global gene regulators (GGRs) selected from the group consisting of sigH, sigL, sigE, ECF-1, and mixtures thereof, wherein the GGR gene is at least partially inactivated. Described herein also is a vaccine based on the mutant and a method of differentiating between subjects that have been infected with mycobacterium and subjects that have not been infected with mycobacterium or have been vaccinated with a mycobacterium vaccine.

The invention discloses a miRNA marker for assistant diagnosis of tuberculosis and application thereof. The invention requires the protection of the application of a substance for detecting miRNAs inserum exosomes in the preparation of products used for diagnosing or assisting the diagnosis of tuberculosis patients or for diagnosing or assisting the diagnosis of active tuberculosis patients, wherein each miRNA refers to one or a combination of the following five kinds of miRNAs: miR-28-3p, miR-193b-5p, miR-370-3p, miR-1246 and miR-2110. The invention also requires the application of the substance for detecting miRNAs in serum exosomes in the preparation of products used for diagnosing or assisting the diagnosis of patients with latent tuberculosis infections, wherein each miRNA refers toone or a combination of the following three kinds of miRNAs: let-7e-5p, let-7d-5p and miR-140-5p. A foundation is laid for further development of the early rapid diagnosis technology and method for tuberculosis.

The invention discloses a curative effect evaluation reagent kit of phthisis, which comprises five elisa plates, a protein standard composition and a biotin labeled antibody composition, wherein the elisa plates are coated with an ALB (Albumin) antibody, an APOA (Lipoprotein A) antibody, a C3 antibody, an ARHGDIB (Rho GDP Dissociation Inhibitor) antibody and an FCN2 (Ficolin-2) antibody respectively; the protein standard composition comprises an ALB protein standard, an APOA protein standard, an ARHGDIB protein standard, a C3 protein standard and an FCN2 protein standard; and the biotin labeled antibody composition comprises a biotin-labeled ALB antibody, a biotin-labeled APOA antibody, a biotin-labeled ARHGDIB antibody, a biotin-labeled C3 antibody and a biotin-labeled FCN2 antibody. The curative effect evaluation reagent kit of the phthisis can evaluate a curative effect of a phthisis patient efficiently and accurately.

The novel aspect of this invention is that it is a unique formulation of naturally occurring compounds with a unique intention to assist the concerns associated with autoimmune conditions, mainly inflammatory bowel disease (collectively Crohn's, ulcerative colitis, irritable bowel syndrome), Type 1 diabetes, Multiple sclerosis, Psoriasis and the suspected infection of the pathogen Mycobacterium avium sub-species paratuberculosis (MAP). Furthermore, its intent is to address the lack of treatment options available for those with aforementioned autoimmune conditions. Specifically, to offer an alternative option that does not pose the amount of negative side effects that may be associated with contemporary treatment methods. The invention will offer a treatment method that is lower in cost as persons with autoimmune conditions conventional treatment methods costs are rising even under most insurance provider's coverage. In addition, the invention offers an available method without the barriers to care most people with autoimmune conditions may encounter. The invention will provide educational information to persons with autoimmune conditions to offer an individual choice in methods of treatment. The invention will offer persons with autoimmune conditions a variety of options as said invention can be utilized con-currently with conventional treatment methods.

The invention discloses an oligonucleotide gene chip and application of the oligonucleotide gene chip to the detection of various bacteria. Probes of the oligonucleotide gene chip can be hybridized with polymerase chain reaction (PCR) amplification products of M. tuberculosis, M. bovis, M. avium, M. paratuberculosis and Brucella respectively; and the probes have nucleotide sequences shown as SEQ ID No:25, SEQ ID No:31, SEQ ID No:35, SEQ ID No:37 and SEQ ID No:39 respectively. The gene chip is applied to the detection of the bacteria and has high repeatability, and interassay and intraassay coefficients of variation (CV) are less than 15 percent. The gene chip shows high accuracy on the detection of a pathogenic bacterium sample to be detected, which indicates that the method has high specificity and sensitivity; the high-throughput and parallel detection is realized; detection results are quick and accurate; the whole process from the preparation of nucleic acid to the finishing of the detection only needs 6 to 8h; and the gene chip has broad prospect in preparing reagents and products for pathogen detection, import and export quarantine and epidemiological analysis.

The invention relates to 12 mycobacterium tuberculosis antigen polypeptides, and antigen epitope polypeptides having polypeptide sequences having at least 90% of the same as each other; the antigen polypeptides or the antigen epitope polypeptides are matched with an immunologic adjuvant to obtain mycobacterium tuberculosis vaccines; the antigen polypeptides or the antigen epitope polypeptides are used as antigens, and monoclonal antibodies are prepared and used for detecting whether the sample contains mycobacterium tuberculosis; nucleic acid sequences of the 12 mycobacterium tuberculosis antigen polypeptides and polynucleotides having the nucleic acid sequences having at least 90% of the same as each other are encoded; gene vaccines containing the nucleic acids and the polynucleotides are prepared. Beneficial effects comprise that the polypeptides can be used for recombined vaccine polypeptides, or be used for development of antigen diagnostic reagents, so as to be beneficial for detection and diagnosis of pulmonary tuberculosis.

Methods are disclosed for the prevention and/or treatment of certain gastrointestinal (GI) diseases, such as Johne's Diseases (JD) in animals and Crohn's Disease (CD) in human. Administration of certain probiotic bacteria, such as lactic acid producing bacteria, to animals helps inhibit GI infection by Mycobacterium avium subsp. paratuberculosis (MAP). MAP is the primary pathogenic agent suspected of causing various inflammatory bowel diseases in cattle or humans.

A composition and method for detecting Mycobacterium infection are disclosed. The gcpE, pstA, kdpC, papA2, impA, umaA1, fabG2₁₃2, aceAB, mbtH2, lpqP, map0834c, cspB, lipN, and map 1634 genes of M. paratuberculosis are novel virulence determinants for Johne's disease. Eighteen M. paratuberculosis-specific genomic islands were identified. Twenty-four M. avium-specific genomic islands were identified. Inversion of three large genomic fragments (INV) in M. paratuberculosis was also identified. These genomic identifiers represent novel virulence determinants that can be used as diagnostics targets for mycobacterial infection, and could provide suitable targets for vaccine and drug developments against Johne's disease.

The invention concerns the detection of pathogenic mycobacterium comprising Mycobacterium avium subsp. paratuberculosis (Map) and genomic variants in a bulk milk sample, and more particularly a method for herd management that stratifies the risk of bulk tank milk lots derived from diagnostic-tested subgroups potentially containing DNA from pathogenic mycobacterium including Map. The method involves creating defined risk groups (categories) of milk-producing animals, such as dairy cows, for the presence of Map or related genomic variants in their milk. Another aspect of the invention concerns a method to strengthen the ability of milk-producing animals to resist environmental challenges by Map based on identifying those animals that have and maintain a low antibody level to Map using their female progeny as replacement animals.

The invention provides a medicine used for treating influenza, upper respiratory infection and viral pneumonia. The medicine is glycoprotein or a mixture of polysaccharide and protein or polypeptide or protein. The glycoprotein provided by the invention has a stabilization effect on body temperatures of endotoxin pyrogenic domestic rabbits, and has an obvious antipyretic effect; the medicine provided by the invention is used for treating the influenza, the upper respiratory infection and the viral pneumonia, and no symptoms of bronchitis, pneumonia and tuberculosis; the complication is 0; the toxin-free concentration of the medicine to Vero-E6 cells is 100 mu g/ml, and has an obvious inhibition effect on SARS viruses. The medicine provided by the invention has obvious pharmacologic actions on seven aspects of in-vitro virus resistance, in-vivo virus resistance, bacterium inhibition, inflammation resistance, antipyretic action, pain alleviation and immunologic function improvement; the medicine has the characteristics of safety, high efficiency and no side effect and has functions of preventing and treating respiratory system diseases, and broad-spectrum anti-virus, anti-inflammatory, anticoagulation, bacteria resisting, antipyretic and immunity adjusting functions.

Antigens of Mycobacterium avium subsp. paratuberculosis, antigenic compositions include at least two of the antigens, as well as epitopes, antibodies or hypervariable fragments thereof and nucleotide sequences coding for them. The antigens are used in diagnosis and/or vaccination against Mycobacterium avium subsp. paratuberculosis, in mammals, and in particular in cattle, but also in sheep and caprines. The antigens have potential application in diagnosis and/or vaccination against Crohn's disease in humans.

The invention provides application of proteins of Rv3872, Rv0164 and/or Rv1926c in developing and/or designing a product with functions of identification, diagnosis, auxiliary diagnosis, screening and/or auxiliary screening of the active tuberculosis. The invention further provides a protein chip prepared by the proteins of Rv3872, Rv0164 and/or Rv1926c. According to the invention, the protein chip can be used for detecting the levels of IgG antibodies corresponding to three protein antigens in the blood serum of a patient with active tuberculosis and those in the blood serum of a normal person, conjointly analyzing the testing results of antibodies corresponding to the three groups of proteins and judging whether people to be tested have active tuberculosis or not. Test results show that the specificity and the sensitivity of the optimal operating point of the protein chip for auxiliary diagnosis of the active tuberculosis are 91.1% and 82.4% respectively which are both above the diagnosis indexes of the active tuberculosis in prior art.

The invention discloses a reagent and a method for detecting Mycobacterium tuberculosis infection in vitro. The reagent comprises a segment of specific T cell reactive polypeptide, namely M232 polypeptide shown as SEQ ID No.1 and screened from early secreting antigen target-6 (ESAT-6) polypeptide; and the M232 polypeptide is contacted with a T cell of a Mycobacterium tuberculosis host to detect cell factors released by the T cell and determine whether the T cell identifies the M232 polypeptide. The invention has the advantages of high sensitivity, no influence of Bacillus Calmette-Guerin (BCG) vaccine and nontuberculosis mycobacterial vaccine, high specificity, capacity of detecting patients with active pulmonary tuberculosis and patients with potential infection, and capacity of detecting healthy Mycobacterium tuberculosis contacts. The invention is particular suitable for detecting tuberculosis and/or potential infection of the tuberculosis for Chinese people. The invention also relates to a kit for detecting Mycobacterium tuberculosis infection in vitro, which comprises two mixed polypeptides, namely M232 and M233, and a tool for detecting the identification of the T cell on protein, or polypeptide or analogs of the polypeptide.

The invention provides a method for detecting infection of an animal with a microorganism that causes a slow progressive disease, comprising providing the animal with a protein of the microorganism, or a functional part, derivative and/or analogue thereof, and measuring an immune response of the animal directed against the microorganism. With a method of the invention, diagnosis during early stages of an infection has become possible. In one aspect, the microorganism comprises Mycobacterium avium subspecies paratuberculosis. Preferably, the protein comprises a surface-associated protein. Peptides comprising B-cell epitopes of M. avium ssp paratuberculosis heat shock protein 70, nucleic acid molecules encoding such peptides and diagnostic kits comprising a peptide and/or nucleic acid molecule of the invention are also herewith provided.

The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's disease. In addition, the invention also provides as kits for use in the diagnosis of Map infections and vaccines/immunogenic compositions.